Fractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study)

Prior treatment

• Received thrombolytic therapy
• PCI in the previous 30 days or Previous CABG

Other illness

• Cardiac shock or SBP\<90mmHg;
• History of old myocardial infarction;
• Patients with severe valve disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension;
• Not suitable for clinical research:
  • Currently participating in another study that may affect the primary endpoint
  • Pregnant and lactating women;
  • Known allergy to drugs that may be used in the study;
  • Unable to comply with the trial protocol or follow-up requirements; Or the researcher believes that participating in the trial may result in patients facing greater risks.

Lab values

• Patients combined with other serious diseases such as severe renal dysfunction (creatinine clearance value\<30ml/min;), liver dysfunction and thrombocytopenia

Other

• Left main artery lesion, non infarct related vessels are CTO lesions;
• Patients who cannot give informed consent or have a life expectancy of less than 1 year

• Age ≥ 18 years
• Patients presenting STEMI and multivessel coronary disease successful primary PCI of the culprit lesion (including those who still have ischemic symptoms within 48 hours)
• Multivessel disease was defined at least one non-culprit coronary arteries with a diameter of 2.5 mm or more and a maximum diameter at least 50% stenosis by visual estimation, PCI can be successfully implemented
• Sign an informed consent form before participating in the study